Halliburton Labs has announced its next set of clean energy tech companies. Photo courtesy of Halliburton

Three climatetech companies will be joining Halliburton Labs, a Houston-based energy transition incubator.

Chemergy, EVA, and Novamera will be joining Halliburton Labs, the company announced last week. The three startups will receive technical support, access to Halliburton's global connections, and more from the program.

“We are excited to help accelerate three innovative companies that emerged from our recent Finalists Pitch Day,” says Dale Winger, managing director of Halliburton Labs, in a news release. “We will work closely with these founders and their teams to achieve strategic, operational, and financial milestones with the most efficient use of their time and capital."

Halliburton Labs launched in the summer of 2020, and now has over a dozen companies working on climatetech solutions in its portfolio. Applications are now open for the next cohort on the Halliburton Labs website and are due by April 22, for the May 20 Finalists Pitch Day.

"In less than two years, we've established productive new relationships with fifteen companies scaling solutions across a breadth of markets to expand our understanding of new value chains,” Winger continues.

Here's a little more about the three new additions to the program.

Chemergy 

Miami-based Chemergy has created a patented HyBrTec process is designed to convert wet organic and plastic wastes into green hydrogen, thereby eliminating the liability and consequences of the wastes by converting them into fuel.

“We see a great opportunity to collaborate with Halliburton Labs' industrial experience to ensure our systems can be installed and operated safely in communities to solve waste disposal issues, improve resiliency and sustainability, and produce cleaner fuel locally,” says Melahn Parker, president of Chemergy.

EVA 

EVA, a New York headquartered company with a presence on four continents, is increasing scalability for the drone industry with its ground infrastructure and operating system solutions that help customers perform inspections, make deliveries, recharge, and monitor remote operations without local manpower.

“The Halliburton Labs ‘scalerator' model comes at the right time for EVA as we accelerate commercialization," says Olivier Le Lann, founder and CEO. "We're excited about the ways Halliburton's global market and industrial expertise will accelerate our trajectory."

Novamera 

Canadian company Novamera has developed proprietary navigation tools and software that enables climate smart, surgical mining and unlocks value in certain mineral deposits found worldwide that are otherwise uneconomic due to their small scale and geometry.

“We are pleased to join Halliburton Labs' accelerator program," says Novamera Co-founder and CEO Dustin Angelo in a news release. "Their engineering expertise and business experience will help us accelerate the development of our technology and scale our business to bring a more sustainable method of mining to the world.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”